Related Experiment Video
Updated: Oct 2, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura
1The Scripps Research Institute, La Jolla, CA 92037, USA. mcmillan@scripps.edu
Abstract:
Treatment of chronic immune (idiopathic) thrombocytopenic purpura with corticosteroids and/or splenectomy results in safe platelet counts in over 70% of patients without additional treatment. Therapy of patients who are refractory to these two treatments may be difficult. The treatment approach to refractory ITP patients, described in this report, is arbitrarily divided into four levels: levels 1 through 3 represent treatments with increasing side effects; level 4 therapy may be tried when the others have failed. Patients undergoing these treatments may require concomitant intravenous gammaglobulin, high-dose corticosteroids or platelets, to maintain the platelet count in the setting of mucosal bleeding or severe thrombocytopenia.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pericarditis III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
